Cannabinoids: A new group of agonists of PPARs

PPAR Research

Volumn , Issue , 2007, Pages

  Sun, Yan ^a   Bennett, Andy ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AJULEMIC ACID; ANANDAMIDE; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; BEZAFIBRATE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CIGLITAZONE; CLOFIBRATE; ENGLITAZONE; FENOFIBRATE; G PROTEIN COUPLED RECEPTOR; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NOLADIN ETHER; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; STEARIC ACID; TETRAHYDROCANNABINOL; TROGLITAZONE; UNINDEXED DRUG; VIRODHAMINE;

ABSENCE OF SIDE EFFECTS; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERTRIGLYCERIDEMIA; MEDICAL RESEARCH; NONHUMAN; REVIEW;

EID: 36949024039     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2007/23513     Document Type: Review

References (45)

1. R. Mechoulam Y. Gaoni Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21 5 1965 1223 1229
2. A. C. Howlett Pharmacology of cannabinoid receptors. Annual Review of Pharmacology Toxicology 1995 35 607 634
3. R. Mechoulam mechou@yam-suff.cc.huji.ac.il E. Fride V. Di Marzo Endocannabinoids. European Journal of Pharmacology 359 1 1998 1 18
4. S. A. Cook J. A. Lowe B. R. Martin CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ9- tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics 285 3 1998 1150 1156
5. T. Nadulski F. Pragst fritz.pragst@charite.de G. Weinberg Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of thc verses standardized cannabis extract. Therapeutic Drug Monitoring 27 6 2005 799 810
6. R. G. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutic 74 1997 129 180
7. B. R. Martin D. R. Compton B. F. Thomas Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry and Behavior 40 3 1991 471 478
8. W. A. Devane A. Breuer T. Sheskin T. U. C. Jarbe M. S. Eisen R. Mechoulam A novel probe for the cannabinoid receptor. Journal of Medicinal Chemistry 35 11 1992 2065 2069
9. D. M. Lambert lambert@cmfa.ucl.ac.be C. J. Fowler The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. Journal of Medicinal Chemistry 48 16 2005 5059 5087
10. K.-O. Jonsson S. Vandevoorde D. M. Lambert G. Tiger C. J. Fowler Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. British Journal of Pharmacology 133 8 2001 1263 1275
11. A. C. Howlett F. Barth T. I. Bonner International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 54 2 2002 161 202
12. J. L. Wiley jwiley@hsc.vcu.edu B. R. Martin Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids 121 1-2 2002 57 63
13. D. Smart J. C. Jerman Anandamide: an endogenous activator of the vanilloid receptor. Trends in Pharmacological Sciences 21 4 2000 134
14. A. Calignano R. G. La D. Piomelli piomelli@uci.edu Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European Journal of Pharmacology 419 2-3 2001 191 198
15. V. Di Marzo C. S. Breivogel Q. Tao Levels, metabolism, and pharmacologicalactivity of anandamide in CB(1) cannabinoid receptor knockoutmice: evidence for non-CB(1), non-CB(2) receptor-mediated actionsof anandamide in mouse brain. Neurochemical Research 75 6 2000 2434 2444
16. C. S. Breivogel G. Griffin V. Di Marzo B. R. Martin R. K. Razdan A. M. Zimmer A. Zimmer B. R. Martin Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60 1 2001 155 163
17. E. B. Russo A. Burnett B. Hall K. K. Parker keith.parker@umontana.edu Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research 30 8 2005 1037 1043
18. S. S. Davies A. V. Pontsler G. K. Marathe Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists. Journal of Biological Chemistry 276 19 2001 16015 16023
19. M. Gottlicher E. Widmark Q. Li J.-A. Gustafsson Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 89 10 1992 4653 4657
20. K. Yu W. Bayona C. B. Kallen Differential activation of peroxisome proliferator-activated receptors by eicosanoids. Journal of Biological Chemistry 270 41 1995 23975 23983
21. M. V. Chakravarthy Z. Pan Y. Zhu "New" hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism 1 5 2005 309 322
22. B. M. Forman J. Chen R. M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proceedings of the National Academy of Sciences of the United States of America 94 9 1997 4312 4317
23. T. M. Willson J. E. Cobb D. J. Cowan The structure-activityrelationship between peroxisome proliferator-activated receptor gammaagonism and the antihyperglycemic activity of thiazolidinediones. Journal Medical Chemistry 39 1996 665 668
24. W. R. Oliver Jr. J. L. Shenk M. R. Snaith A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 98 2001 5306 5311
25. J. Fu jinf@uci.edu F. Oveisi S. Gaetani E. Lin D. Piomelli Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48 8 SPEC. ISS. 2005 1147 1153
26. J. Fu S. Gaetani F. Oveisi Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α Nature 425 6953 2003 90 93
27. M. Guzmàn V. J. Lo J. Fu F. Oveisi C. Blàzquez D. Piomelli piomelli@uci.edu Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor (PPAR-α). Journal of Biological Chemistry 279 27 2004 27849 27854
28. S. E. O'Sullivan Saoirse.o'sullivan@nottingham.ac.uk E. J. Tarling A. J. Bennett D. A. Kendall M. D. Randall Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications 337 3 2005 824 831
29. R. B. Zurier R. G. Rossetti J. H. Lane J. M. Goldberg S. A. Hunter S. H. Burstein Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis and Rheumatism 41 1 1998 163 170
30. J. Liu H. Li S. H. Burstein R. B. Zurier J. D. Chen Activation and binding of peroxisome proliferator-activated receptor gamma by syntheticcannabinoid ajulemic acid. Molecular Pharmacology 63 2003 983 992
31. F. Maingret A. J. Patel M. Lazdunski E. Honorè The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. EMBO Journal 20 1-2 2001 47 54
32. V. Di Marzo A. Fontana H. Cadas Formation and inactivation of endogenous cannabinoid anandanide in central neurons. Nature 372 6507 1994 686 691
33. C. J. Fowler cf@pharm.umu.se G. Tiger A. Ligresti M. L. Lòpez-Rodrìguez V. Di Marzo Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. European Journal of Pharmacology 492 1 2004 1 11
34. V. Di Marzo VDM@TRINC.ICMIB.NA.CNR.IT T. Bisogno P. L. De D. Melck B. R. Martin Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids. Current Medicinal Chemistry 6 8 1999 721 744
35. S. H. Burstein sumner.burstein@umassmed.edu R. G. Rossetti B. Yagen R. B. Zurier Oxidative metabolism of anandamide. Prostaglandins and Other Lipid Mediators 61 1-2 2000 29 41
36. M. Bouaboula S. Hilairet J. Marchand L. Fajas G. Le Fur P. Casellas pierre.casellas@sanofi-aventis.com Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology 517 3 2005 174 181
37. Y. Sun stxys3@nottingham.ac.uk S. P. H. Alexander D. A. Kendall A. J. Bennett Cannabinoids and PPARα signalling. Biochemical Society Transactions 34 6 2006 1095 1097
38. V. J. Lo J. Fu G. Astarita The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology 67 1 2005 15 19
39. C. E. Rockwell N. T. Snider J. T. Thompson J. P. Vanden Heuvel N. E. Kaminski kamins11@msu.edu Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Molecular Pharmacology 70 1 2006 101 111
40. S. Vandevoorde D. M. Lambert lambert@cmfa.ucl.ac.be Focus on the three key enzymes hydrolysing endocannabinnoids as new drug targets. Current Pharmaceutical Design 11 20 2005 2647 2668
41. N. Ueda nueda@kms.ac.jp K. Yamanaka S. Yamamoto Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. Journal of Biological Chemistry 276 38 2001 35552 35557
42. J. Lengqvist U. A. Mata De A.-C. Bergman Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain. Molecular and Cellular Proteomics 3 7 2004 692 703
43. D. Rueda I. Galve-Roperh A. Haro M. Guzman The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Molecular Pharmacology 58 4 2000 814 820
44. L. Gelman L. Michalik B. Desvergne W. Wahli walter.wahli@unil.ch Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Current Opinion in Cell Biology 17 2 2005 216 222
45. R. G. Pertwee rgp@abdn.ac.uk The pharmacology of cannabinoid receptors and their ligands: an overview. International Journal of Obesity 30, suppl. 1 2006 S13 S18